Pfizer Inc.has announced that the FDA approved Eucrisa (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor for the...
Pfizer announced top-line results from a Phase IV study (CrisADe CARE 1) which showed that Eucrisa (crisaborole ointment, 2%) was...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...